Xarelto on Prevention of Stroke and Noncentral Nervous System systeMIc Embolism in Treatment Naïve Asian Patients With Non-valvular Atrial Fibrillation
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism; Stroke
- Focus Adverse reactions
- Acronyms XaMINA
- Sponsors Bayer
- 05 Nov 2019 Planned End Date changed from 31 Oct 2019 to 20 Nov 2019.
- 23 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 24 Sep 2018 Planned End Date changed from 31 Dec 2019 to 31 Oct 2019.